OA10909A - Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone) its preparation and its use as dopamine d2 antagonist - Google Patents

Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone) its preparation and its use as dopamine d2 antagonist Download PDF

Info

Publication number
OA10909A
OA10909A OA9800206A OA9800206A OA10909A OA 10909 A OA10909 A OA 10909A OA 9800206 A OA9800206 A OA 9800206A OA 9800206 A OA9800206 A OA 9800206A OA 10909 A OA10909 A OA 10909A
Authority
OA
OAPI
Prior art keywords
ziprasidone
indol
dihydro
benzisothiazol
piperazinyl
Prior art date
Application number
OA9800206A
Other languages
English (en)
French (fr)
Inventor
Frank Robert Busch
Carol Anne Rose
Russell James Shine
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA10909A publication Critical patent/OA10909A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
OA9800206A 1996-05-07 1998-10-30 Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone) its preparation and its use as dopamine d2 antagonist OA10909A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
OA10909A true OA10909A (en) 2001-10-26

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800206A OA10909A (en) 1996-05-07 1998-10-30 Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone) its preparation and its use as dopamine d2 antagonist

Country Status (41)

Country Link
US (1) US6245765B1 (ru)
EP (1) EP0918772B1 (ru)
JP (1) JP3494659B2 (ru)
KR (1) KR100333215B1 (ru)
CN (1) CN1091769C (ru)
AP (1) AP765A (ru)
AR (1) AR007004A1 (ru)
AT (1) ATE278689T1 (ru)
AU (1) AU731267B2 (ru)
BG (1) BG63544B1 (ru)
BR (1) BR9709889A (ru)
CA (1) CA2252898C (ru)
CO (1) CO4940466A1 (ru)
CZ (1) CZ289215B6 (ru)
DE (1) DE69731094T2 (ru)
DK (1) DK0918772T3 (ru)
DZ (1) DZ2222A1 (ru)
EA (1) EA001190B1 (ru)
EG (1) EG24076A (ru)
ES (1) ES2229342T3 (ru)
GT (1) GT199700052A (ru)
HK (1) HK1017892A1 (ru)
HR (1) HRP970236B1 (ru)
ID (1) ID16867A (ru)
IL (1) IL126591A (ru)
IS (1) IS2080B (ru)
MA (1) MA24171A1 (ru)
MY (1) MY119997A (ru)
NO (1) NO312514B1 (ru)
NZ (1) NZ332218A (ru)
OA (1) OA10909A (ru)
PL (1) PL188330B1 (ru)
PT (1) PT918772E (ru)
SI (1) SI0918772T1 (ru)
SK (1) SK282837B6 (ru)
TN (1) TNSN97074A1 (ru)
TR (1) TR199802240T2 (ru)
TW (1) TW491847B (ru)
UA (1) UA46840C2 (ru)
WO (1) WO1997042191A1 (ru)
ZA (1) ZA973876B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (ru) 1996-05-07 2003-07-15 Пфайзер Інк. Комплексы включения арилгетероциклических солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EP1468686B1 (en) * 2000-06-02 2006-11-22 Pfizer Products Inc. S-methyl-dihydro-ziprasidone for treatment of psychiatric disorders
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
CA2525366A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
KR100880279B1 (ko) 2003-06-03 2009-01-28 테바 파마슈티컬 인더스트리즈 리미티드 결정성 지프라시돈 염산염 및 그의 제조 방법
EP1628973A2 (en) 2003-10-24 2006-03-01 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
MXPA06013163A (es) * 2004-05-11 2007-02-13 Pfizer Prod Inc Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
ES2526092T3 (es) * 2004-11-16 2015-01-05 Alkermes Pharma Ireland Limited Formulaciones de olanzapina en nanopartículas inyectables
EP1863806A1 (en) * 2005-02-11 2007-12-12 Teva Pharmaceutical Industries Ltd Amorphous ziprasidone mesylate
EP1742943A1 (en) * 2005-02-11 2007-01-17 Teva Pharmaceutical Industries Ltd Process of preparing ziprasidone mesylate
JP2008531721A (ja) * 2005-03-03 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド 複素環式アミド誘導体のナノ粒子状組成物
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
EP1858891A2 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
EP2146577A1 (en) * 2007-05-18 2010-01-27 Scidose, Llc Ziprasidone formulations
JP2011526881A (ja) * 2008-06-25 2011-10-20 ファイザー・インク ジアリール化合物およびそれらの使用
CA2814840C (en) * 2010-10-18 2018-08-28 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CA2891122C (en) 2012-11-14 2021-07-20 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
UA47467C2 (ru) 1996-05-07 2002-07-15 Файзер Інк. Translated By PlajТРИГИДРАТ МЕЗИЛАТА 5-(2-(4-(1,2-БЕНЗИЗОТИАЗОЛ-3-ИЛ)-1-ПИПЕРАЗИНИЛ)ЭТИЛ)-6-ХЛОР-1,3-ДИГИДРО-2(1Н)-ИНДОЛ-2-ОНА (ЗИПРАЗИДОНА), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ПСИХИЧЕСКИХ РАССТРОЙСТВ

Also Published As

Publication number Publication date
NO312514B1 (no) 2002-05-21
EA199800912A1 (ru) 1999-04-29
KR20000010824A (ko) 2000-02-25
CA2252898A1 (en) 1997-11-13
IS4874A (is) 1998-10-20
SK150898A3 (en) 2000-02-14
UA46840C2 (uk) 2002-06-17
HRP970236B1 (en) 2002-12-31
AP765A (en) 1999-09-17
TW491847B (en) 2002-06-21
AU731267B2 (en) 2001-03-29
CZ289215B6 (cs) 2001-12-12
BR9709889A (pt) 1999-08-10
SK282837B6 (sk) 2002-12-03
IS2080B (is) 2006-02-15
CZ349398A3 (cs) 1999-09-15
NO985194L (no) 1998-11-06
EG24076A (en) 2008-05-11
BG63544B1 (bg) 2002-04-30
DE69731094T2 (de) 2006-02-23
IL126591A (en) 2001-11-25
PL188330B1 (pl) 2005-01-31
BG102892A (en) 1999-09-30
EP0918772B1 (en) 2004-10-06
EP0918772A1 (en) 1999-06-02
CO4940466A1 (es) 2000-07-24
WO1997042191A1 (en) 1997-11-13
GT199700052A (es) 2001-08-29
CN1216991A (zh) 1999-05-19
DK0918772T3 (da) 2005-01-10
US6245765B1 (en) 2001-06-12
TNSN97074A1 (fr) 2005-03-15
HK1017892A1 (en) 1999-12-03
AU2174797A (en) 1997-11-26
AR007004A1 (es) 1999-10-13
ID16867A (id) 1997-11-20
PL329884A1 (en) 1999-04-12
NO985194D0 (no) 1998-11-06
HRP970236A2 (en) 1998-06-30
JPH11509867A (ja) 1999-08-31
PT918772E (pt) 2004-12-31
KR100333215B1 (ko) 2002-06-20
SI0918772T1 (en) 2005-02-28
MA24171A1 (fr) 1997-12-31
ZA973876B (en) 1998-11-06
IL126591A0 (en) 1999-08-17
DE69731094D1 (de) 2004-11-11
NZ332218A (en) 2005-02-25
ATE278689T1 (de) 2004-10-15
MY119997A (en) 2005-08-30
DZ2222A1 (fr) 2002-12-03
CN1091769C (zh) 2002-10-02
EA001190B1 (ru) 2000-12-25
ES2229342T3 (es) 2005-04-16
CA2252898C (en) 2003-04-08
JP3494659B2 (ja) 2004-02-09
TR199802240T2 (ru) 1999-02-22
AP9700976A0 (en) 1997-07-31

Similar Documents

Publication Publication Date Title
OA10909A (en) Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one (=ziprasidone) its preparation and its use as dopamine d2 antagonist
AP838A (en) Mesylate trihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-y1)-1-piperaziny1)-ethy1) -6-chloro-1,3-dihydro-2h-indol-2-one.
NZ508304A (en) Mesylate dihydrate salt of 5-(2-(4-(1,2 benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1H)-indol-2-one ( ziprasidone) useful as dopamine D2 antagonist
JP2022552329A (ja) 化合物の塩及びその結晶形態
MXPA98009242A (en) Salt mesylate trihydrate 5 - (- 2- (4- (1,2-benzoisotiazol-3-il) -1-piperazinil) ethyl) -6-chlorine-1,3-dihydro-2h-indol-2-